Cinterra Names Michael Rothwell as Chief Financial Officer Following Interim Tenure
With more than 25 years of experience leading finance in complex construction, infrastructure, and private equity–backed environments, Rothwell brings a disciplined, execution-oriented approach to Cinterra's finance organization. His background includes executive finance leadership roles where he built high-performing accounting teams, improved financial controls, and supported businesses through periods of rapid growth, capital expansion, and organizational transformation.
"Mike brings the kind of financial leadership that creates confidence across the board," said
As CFO, Rothwell will lead all aspects of financial planning and reporting, capital management, cash flow strategy, compliance, and enterprise risk. His priority will be to build and maintain strong financial systems that support Cinterra's national growth while protecting long-term enterprise value.
"I'm honored to step into this role and continue building on the momentum we've created," said
Rothwell's appointment comes as Cinterra continues its expansion across new markets and deepens its commitment to reliability, discipline, and client satisfaction.
About Cinterra
Cinterra, formerly Directional Services, Inc. (DSI), provides specialized electrical infrastructure and utility-scale solar renewable energy development services to some of the nation's leading energy providers, EPCs, private industry, and public utilities. The company offers construction, operation, and maintenance services that bring electric power and renewable energy to millions across
View original content to download multimedia:https://www.prnewswire.com/news-releases/cinterra-names-michael-rothwell-as-chief-financial-officer-following-interim-tenure-302560894.html
SOURCE Cinterra
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mini PC Brand VZMORE Makes Global Debut at ShowStoppers @ IFA 2026, Bringing Advanced Thermal Innovation to Mini PCs
- Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
- Mitsubishi Electric to Exhibit at Carbon Capture Technology World Expo 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share